Benzimidazole compound and application thereof

By designing a new benzimidazole compound, the problem of insufficient biological activity of NLRP3 inflammasome inhibitors in the prior art was solved, effective inhibition of NLRP3 inflammasomes was achieved, and the production of IL-1β was significantly reduced. High biological activity and anti-inflammatory effects were demonstrated.

CN119060050APending Publication Date: 2024-12-03CHINA PHARM UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411172793.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

When existing benzimidazole compounds block the interaction between NLRP3 and NEK7, there is still room for improvement in biological activity, and it is difficult to effectively inhibit the initiation and activation stage of NLRP3 inflammasomes.

Method used

A new benzimidazole compound has been developed, which can exert inhibitory effects during the initiation and activation stage of NLRP3 inflammasomes through specific molecular structure design. The specific structure is general formula (I) or (II), which can Pharmaceutical formation of acceptable salt forms is used to prepare drugs that inhibit NLRP3 inflammasome-related diseases.

Benefits of technology

This compound significantly inhibited the expression and secretion of IL-1β, reduced the production of IL-1β in THP-M cells induced by LPS and ATP, and showed high biological activity and effective anti-inflammatory effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060050A_ABST
    Figure CN119060050A_ABST
Patent Text Reader

Abstract

The invention discloses a benzimidazole compound and application thereof. The compound is shown as a formula (I) or (II). The compound provided by the invention can inhibit inflammasome, has high activity of targeting NLRP3 inflammasome, and can be used for preparing drugs for treating NLRP3 inflammasome related diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a compound and a preparation method and application thereof, in particular to a benzimidazole compound and application thereof, belonging to the field of pharmaceutical compounds. Background Art

[0002] The NLRP3 inflammasome has been extensively studied in the field of inflammation and is one of the most intensively studied areas. The NLRP3 inflammasome is a protein complex composed of the NLRP3 protein, the apoptosis-associated speck-like protein (ASC) domain, and the cysteine-containing aspartate specific proteinase-1 (Caspase-1). NLRP3 mainly includes the N-segment pyrin domain (PYD), the middle NACHT domain (nucleoside triphosphatase domain), and the C-terminal LRR (leucine-rich repeat) domain. ASC contains two conserved domains: the PYD domain and the caspase recruitment domain (CARD). The ASC domain acts as a bridge between NLRP3 and pro-caspase-1, binding to the upstream NLRP3 protein and pro-caspase-1 through PYD-PYD and CARD-CARD homotypic interactions, respectively. Pro-caspase-1 is composed of a CARD domain and a p20-p10 domain. The p20-p10 domain can break down to generate p20 and p10 under activation conditions, transforming into mature caspase-1. NLRP3 proteins oligomerize and recruit the ASC domain. The ASC domain then polymerizes to assemble a single, massive fibrous structure called the "ASC speckle," which binds to caspase-1 and makes it accessible to induce activation. Once activated, caspase-1 cleaves pro-IL-1β and pro-IL-18 into cognate inflammatory cytokines and cleaves Gasdermin D (GSDMD). GSDMD cleavage releases the pore-forming N-terminal region from the autoinhibitory C-terminal domain, ultimately leading to cell pyroptosis.

[0003] Through a deep understanding of the NLRP3 inflammasome activation pathway, the applicant focused on the process by which NEK7 assists NLRP3 conformational changes. NEK7 bridges the adjacent LRR domains in the closed NLRP3 oligomer, assisting the closed double-ring cage conformation to open and eventually form a disc-shaped NLRP3 active structure.

[0004] Some existing benzimidazole compounds can block the interaction between NLRP3 and NEK7 through their LRR regions. However, the biological activity of imidazopyridine core series compounds still needs to be further improved. Summary of the invention

[0005] Purpose of the invention: The present invention aims to provide a benzimidazole compound with good biological activity; another purpose of the present invention is to provide an application of the benzimidazole compound.

[0006] Technical solution: The compound of the present invention as shown in general formula (I) or (II) or a pharmaceutically acceptable salt thereof:

[0007]

[0008] Among them, R 1 for R a C1-C6 alkylene or -SO2-

[0009] R b is a halogen;

[0010] R 2 for R C is H, C1-C6 alkyl, halogen or -NO2; R d for P is 1-5; q is 0-3;

[0011]

[0012] L is R e is -S-, -SO-, -SO2- or -NH-; R f is absent, C1-C6 alkylene, -SO2- or -CO-(carbonyl); wherein, when Rf is absent, L is

[0013] R 3 for R g It is a benzene ring, a 4-6 membered aliphatic ring or a 4-5 membered heterocyclic ring containing an oxygen atom;

[0014] R h is halogen, H, C1-C6 alkyl, C1-C6 alkoxy, -CN, trifluoromethyl or -O-CF3;

[0015] R 4 for R iIt is a C1-C6 alkyl group or a C2-C4 alkenyl group.

[0016] Preferably, L is Among them, close to R e The connecting bond is connected to the imidazopyridine core, close to R f The connection key with R 3 connect.

[0017] Furthermore, R 1 for R a is C1-C3 alkylene or -SO2-,

[0018] R b is a halogen;

[0019] R 2 for R C is H, C1-C3 alkyl, halogen or -NO2; R d for P is 1-5; q is 0-3;

[0020]

[0021] Among them, L is R e is -S-, -SO-, -SO2- or -NH-; R f is absent, C1-C6 alkylene, -SO2- or -CO-;

[0022] R 3 for R g It is a benzene ring, a 4-6 membered aliphatic ring or a 4-5 membered heterocyclic ring containing an oxygen atom;

[0023] R h is halogen, H, C1-C3 alkyl, C1-C3 alkoxy, -CN, trifluoromethyl or -O-CF3;

[0024] R 4 for R i It is C1-C3 alkyl or C2-C4 alkenyl.

[0025] Furthermore, R 1 for R a is methylene or -SO2-,

[0026] R b is F, Cl, Br or I;

[0027] R 2 for RC is H, F, Cl, Br or I, methyl, propyl, -NO2; R d for p is 1, 2, 3, 4 or 5; q is 0, 1, 2 or 3.

[0028] Preferably, R 1 Selected from:

[0029]

[0030] R 2 Selected from:

[0031]

[0032] Further,

[0033]

[0034] L is R e is -S-, -SO-, -SO2- or -NH-; R f is absent, methylene (-CH2-), -SO2- or -CO-

[0035] R 3 for R g It is a benzene ring, a cyclopentyl group, a cyclohexyl group or a 4-membered heterocyclic ring containing one oxygen atom and three carbon atoms;

[0036] R h is F, Cl, Br, I, H, methyl, methoxy, -CN, trifluoromethyl, -O-CF3;

[0037] R 4 for R d for P is 1, 2, 3, 4 or 5; q is 0, 1, 2 or 3; R i It is ethyl or vinyl.

[0038] Preferably,

[0039] L is selected from:

[0040] R 3 Selected from:

[0041] R 4 Selected from:

[0042] Preferably, L is selected from: The left connecting bond of each of the above groups is connected to the imidazopyridine core, and the right connecting bond is connected to R 3 connect.

[0043] In another aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, selected from any of the following structures:

[0044]

[0045]

[0046]

[0047] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

[0048] On the other hand, the present invention provides a use of the above-mentioned compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating NLRP3 inflammasome-related diseases.

[0049] Preferably, the NLRP3 inflammasome-related disease is selected from chronic inflammation, autoimmunity, metabolic diseases, neurodegenerative diseases, gout, pseudogout, atherosclerosis, non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, type 2 diabetes, Alzheimer's disease, Parkinson's disease, multiple sclerosis, renal injury, renal fibrosis, acute and chronic heart failure, liver fibrosis, liver injury, inflammatory bowel disease, rheumatoid arthritis, cardiovascular and cerebrovascular diseases, etc.

[0050] On the other hand, the present invention provides a use of the above-mentioned compound or a pharmaceutically acceptable salt thereof in the preparation of an NLRP3 inflammasome inhibitor.

[0051] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: the compound of the present invention has high biological activity and can play an inhibitory role in both the initiation and activation stages of the NLRP3 inflammasome. In the initiation stage, it may inhibit the expression of IL-1β in the initiation stage, thereby reducing the production of inflammatory mediators; in the activation stage, it significantly reduces the secretion of IL-1β in THP-M cells induced by LPS and ATP. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 The IC of compound JM-31 inhibiting NLRP3 inflammasome 50 The THP-M cells were treated with different concentrations of compounds for 24 h, then treated with LPS for 3 h and ATP for 1 h. The ELISA method was used to detect the IL-1β content in the cell supernatant and the IC 50Three independent experiments were performed for each concentration, and the data are presented as mean±sem (n=3).

[0053] Figure 2 This study explored the inhibitory effect of compound JM-31 on NLRP3 inflammasome. Western Blot analysis was used to analyze the effect of compound JM-31 on the levels of key proteins in the NLRP3 inflammasome pathway.

[0054] Figure 3 The effect of compound JM-31 on different stages of the NLRP3 inflammasome pathway. THP-M cells were treated with compound JM-31 for 24 h before (a) and after (b) LPS treatment for 3 h, and then treated with ATP for 1 h. The ELISA method was used to detect the IL-1β content in the cell supernatant. Each data represents three independent experiments, expressed as mean±sem (n=3), **p<0.01, ***p<0.001, ****p<0.0001.

[0055] Figure 4 The effect of compound JM-31 on the transcription level of key proteins in the NLRP3 inflammasome pathway. After THP-M cells were treated with compound JM-31 for 24 hours, LPS was used for 4 hours, and the levels of NLRP3 and IL-β were detected by RT-qPCR, with GAPDH as the internal reference. Each data represents three independent experiments, expressed as mean±sem (n=3), NS: not significant, *p<5, **p<0.01. DETAILED DESCRIPTION

[0056] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.

[0057] The following Examples 1-32 are syntheses of intermediates.

[0058] Example 1 Synthesis of Intermediate 2

[0059] Synthesis of 3H-imidazo[4,5-b]pyridine-2-thiol (2)

[0060]

[0061] Weigh 2,3-diaminopyridine (1.0 g, 9.16 mmol) and dissolve it in a mixed solution of ethanol and water (12 mL). Add potassium hydroxide (514.10 mg, 9.16 mmol) and carbon disulfide (1.40 g, 18.33 mmol) and stir in a sand bath at 80°C for 8 h until the reaction of raw material 1 is complete as detected by TLC. Cool the reaction solution to room temperature, adjust the solution pH to weak acidity, and stand for 2 h to precipitate a black precipitate, which is filtered out and dried in vacuum. 1.08 g of black solid is obtained, with a yield of 78%.

[0062] Example 2 Synthesis of Intermediate 3

[0063] Synthesis of 2-((Cyclohexylmethyl)thio)-3H-imidazo[4,5-b]pyridine (3)

[0064]

[0065] Weigh the intermediate 2 (0.5 g, 3.31 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (701.04 mg, 6.61 mmol) and stir in a sand bath at 45 ° C for 1 h. Then slowly add bromomethylcyclohexane (708.78 mg, 3.97 mmol) dropwise, and continue the reaction until the reaction of raw material 2 is complete according to TLC. The reaction mixture is cooled to ambient temperature, and then a large amount of water is added to dilute it. Adjust the pH of the solution to near neutral, extract with EA three times, combine the organic phases, wash with a saturated solution of NaCl, and dry with anhydrous Na2SO4. Purify by column chromatography of DCM-MeOH system to obtain 0.45 g of dark brown solid with a yield of 55%. 1 H NMR(300MHz, DMSO-d6)δ(ppm):12.93(d,J=139.9Hz,1H),8.19(d,J=32.2Hz,1H),7.90–7.66(m,1H),7.13(t,J=6.5H z,1H),3.23(d,J=6.9Hz,2H),1.89–1.79(m,2H),1.73–1.55(m,4H),1.27–1.09(m,3H),1.02(qd,J=12.1,3.4Hz,2H).

[0066] Example 3 Synthesis of Intermediate 5

[0067] Synthesis of 2-((4-fluorophenyl)thio)-1H-benzo[d]imidazole (5)

[0068]

[0069] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 50 °C for 0.5 h. Then slowly add 4-fluorobenzyl bromide (496.78 μL, 3.99 mmol) and continue the reaction until the reaction of raw material 4 is complete according to TLC. After the reaction solution is cooled, add a large amount of water to dilute and adjust the solution pH to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. After filtering, the PE-EA system is pulped and purified to obtain 0.80 g of white crystalline solid with a yield of 93%. 1H NMR (300MHz, DMSO-d6) δ (ppm): 7.47 (m, 4H), 7.18–7.07 (m, 4H), 4.55 (s, 2H).

[0070] Example 4 Synthesis of Intermediate 6

[0071]

[0072] Synthesis of 2-((Cyclohexylmethyl)thio)-1H-benzo[d]imidazole (6)

[0073] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in N,N-dimethylformamide (2 mL). Add anhydrous sodium carbonate (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly add bromomethylcyclohexane (561.43 μL, 3.99 mmol) dropwise and continue the reaction until the reaction of raw material 4 is complete by TLC. After the reaction solution is cooled, add a large amount of water to dilute and adjust the solution pH to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. Purify by PE-EA system column chromatography to obtain a white needle-shaped solid. 1 H NMR (300MHz, Chloroform-d) δ (ppm): 7.50 (s, 2H), 7.19 (dd, J = 6.0, 3.2Hz, 2H), 3.27 (d, J =6.9Hz,2H),1.88(d,J=12.5Hz,2H),1.68(m,4H),1.33–1.13(m,3H),1.13–0.94(m,2H).

[0074] Example 5 Synthesis of Intermediate 8

[0075] Synthesis of 2-((Cyclohexylmethyl)thio)-1H-imidazole (8)

[0076]

[0077] Weigh 2-mercaptoimidazole (0.5 g, 4.99 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (1.06 mg, 9.99 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly add bromomethylcyclohexane (1.33 g, 7.49 mmol) dropwise and continue the reaction until the reaction of raw material 7 is complete as detected by TLC. After the reaction solution is cooled, add a large amount of water to dilute it, adjust the solution pH to near neutral, extract with EA three times, combine the organic phases and wash with saturated brine. Purify by PE-EA system column chromatography to obtain 0.42 g of white crystalline solid with a yield of 43%. 1HNMR(300MHz,DMSO-d6)δ(ppm):12.15(s,1H),7.11(s,1H),6.90(s,1H),2.88(d,J=6.8Hz,2 H),1.82–1.72(m,2H),1.70–1.57(m,1H),1.43(m,1H),1.21–1.04(m,3H),1.01–0.83(m,2H).

[0078] Example 6 Synthesis of Intermediate 9

[0079] Synthesis of 2-((4-fluorobenzyl)thio)-1H-imidazole (9)

[0080]

[0081] Weigh 2-mercaptoimidazole (0.5 g, 4.99 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (1.06 mg, 9.99 mmol) and stir in a sand bath at 50 °C for 1 h. Then slowly add 4-bromobenzyl bromide (1.50 g, 5.99 mmol) dropwise and continue the reaction until the reaction is complete as detected by TLC. After the reaction solution is cooled, add a large amount of water to dilute it, adjust the pH of the solution to near neutral, extract with EA three times, combine the organic phases, wash with a saturated sodium chloride solution and dry. Purify by PE-EA system column chromatography to obtain 0.83 g of white crystalline solid with a yield of 62%. 1 HNMR (300MHz, DMSO-d6) δ (ppm): 12.22 (s, 1H), 7.45 (m, 2H), 7.23–7.08 (m, 3H), 6.94 (s, 1H), 4.19 (s, 2H).

[0082] Example 7 Synthesis of Intermediate 11

[0083] Synthesis of N-(4-fluorobenzyl)-2-nitroaniline (11)

[0084]

[0085] Weigh 2-mercaptoimidazole (2.0 g, 14.48 mmol) and dissolve it in N,N-dimethylformamide (20 mL). Add K2CO3 (2.40 mg, 17.38 mmol) under ice bath conditions, then slowly add 4-fluorobenzyl bromide (2.74 g, 14.48 mmol) in drops, and heat at 60°C until the reaction is complete as detected by TLC. After the reaction solution is cooled, add a large amount of water to dilute, adjust the solution pH to near neutral, extract with EA three times, combine the organic phases, and wash with saturated brine. Concentrate under reduced pressure, purify with PE-EA system column chromatography, and obtain 2.40 g of yellow oil with a yield of 67%.

[0086] Example 8 Synthesis of Intermediate 12

[0087] Synthesis of 1-(4-fluorobenzyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (12)

[0088]

[0089] Intermediate 11 (2.40 g, 9.75 mmol) was dissolved in anhydrous ethanol (20 mL), and iron powder (2.72 g, 48.73 mmol) and a saturated solution of ammonium chloride were added under stirring at room temperature. Refluxed at 85 ° C for 3-4 h until the reaction of the raw material was complete by TLC. The solid in the reaction system was filtered off with diatomaceous earth, the solvent was dried and diluted with an appropriate amount of water, extracted with EA three times, and the organic phases were combined and washed with a saturated solution of sodium chloride. The solvent was dried and dissolved in anhydrous tetrahydrofuran (10 mL), and N, N-carbonyldiimidazole (4.75 g, 29.27 mmol) was added and stirred at room temperature overnight. After the reaction of the raw material was complete, the solvent was dried and vacuum dried to obtain a yellow solid.

[0090] Example 9 Synthesis of Intermediate 13

[0091] Synthesis of 4-Fluoro-N-(2-nitrophenyl)benzenesulfonamide (13)

[0092]

[0093] Slowly add 4-fluorobenzenesulfonyl chloride (2.82 g, 14.48 mmol) to a solution of o-nitroaniline (2.0 g, 14.48 mmol) in anhydrous pyridine (10 mL), and stir in a sand bath at 125°C for 6 h until all the raw materials react. After the reaction solution is cooled, add a large amount of water to dilute, extract with EA, combine the organic phases, wash with a saturated solution of NaCl, and then dry with anhydrous sodium sulfate. Purify by PE-EA system column chromatography to obtain 4.0 g of yellow solid with a yield of 93%.

[0094] Example 10 Synthesis of Intermediate 14

[0095] Synthesis of 1-((4-fluorophenyl)sulfonyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (14)

[0096]

[0097] Intermediate 13 (4.0 g, 13.50 mmol) was dissolved in anhydrous ethanol (30 mL), and iron powder (3.77 g, 67.51 mmol) and a saturated solution of ammonium chloride were added under stirring at room temperature. Refluxed at 85 ° C for 3-4 h until the reaction of the raw material was complete by TLC. The solid was filtered off with diatomaceous earth, and the solvent was dried and added with an appropriate amount of water. After EA extraction, the organic phases were combined and washed with a saturated solution of NaCl. Drying with anhydrous sodium sulfate. The solvent was dried and dissolved in anhydrous tetrahydrofuran (10 mL), and N, N-carbonyldiimidazole (6.58 g, 40.56 mmol) was added and stirred at room temperature overnight. After the reaction of the raw material was complete, the solvent was dried and vacuum dried to obtain a yellow solid.

[0098] Example 11 Synthesis of Intermediate 15

[0099] Synthesis of 2-((4-chlorobenzyl)thio)-1H-benzo[d]imidazole (15)

[0100]

[0101] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 50 min. Slowly drop p-chlorobenzyl bromide (523 μL, 4.00 mmol) and continue the reaction until the reaction of raw material 4 is complete by TLC. After the reaction solution is cooled, add a large amount of water to dilute and adjust the pH of the solution to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.70 g of white solid with a yield of 77%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 12.59 (s, 1H), 7.52–7.31 (m, 6H), 7.13 (m, 2H), 4.55 (s, 2H).

[0102] Example 12 Synthesis of Intermediate 16

[0103] Synthesis of 2-((4-bromobenzyl)thio)-1H-benzo[d]imidazole (16)

[0104]

[0105] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 ml). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly add 4-bromobenzyl bromide (550 μl, 4.02 mmol) in small drops and continue the reaction until the reaction of raw material 4 is complete according to TLC. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the pH of the solution to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 1.01 g of white solid with a yield of 94%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.54–7.36 (m, 6H), 7.12 (m, 2H), 4.54 (s, 2H).

[0106] Example 13 Synthesis of Intermediate 17

[0107] Synthesis of 2-(Benzylthio)-1H-benzo[d]imidazole (17)

[0108]

[0109] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly drop benzyl bromide (475 μL, 4.00 mmol) and continue the reaction until the reaction of raw material 4 is complete by TLC. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the pH of the solution to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.69 g of white solid with a yield of 86%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.49–7.40 (m, 4H), 7.29 (m, 3H), 7.12 (m, 2H), 4.56 (s, 2H).

[0110] Example 14 Synthesis of Intermediate 18

[0111] Synthesis of 2-((4-methylbenzyl)thio)-1H-benzo[d]imidazole (18)

[0112]

[0113] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly drop 4-methylbenzyl bromide (560 μL, 4.01 mmol) and continue the reaction until the reaction of raw material 4 is complete by TLC. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the pH of the solution to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.61 g of white solid with a yield of 72%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.44 (dd, J=5.9, 3.2Hz, 2H), 7.32 (d, J=7.7Hz, 2H), 7.18–7.03 (m, 4H), 2.25 (s, 3H).

[0114] Example 15 Synthesis of Intermediate 19

[0115] Synthesis of 2-((4-methoxybenzyl)thio)-1H-benzo[d]imidazole (19)

[0116]

[0117] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly drop 4-methoxybenzyl bromide (583 μL, 4.00 mmol) and continue the reaction until the reaction of raw material 4 is complete. After the reaction solution is cooled, add a large amount of water to dilute and adjust the solution pH to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.45 g of white solid with a yield of 50%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 12.54 (s, 1H), 7.44 (s, 2H), 7.36 (d, J = 8.3Hz, 2H), 7.12 (m, 2H), 6.86 (d, J = 8.3Hz, 2H), 4.51 (s, 2H), 3.71 (s, 3H).

[0118] Example 16 Synthesis of Intermediate 20

[0119] Synthesis of 2-((4-(trifluoromethyl)benzyl)thio)-1H-benzo[d]imidazole (20)

[0120]

[0121] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in N, N-dimethylformamide (2 ml). Add anhydrous sodium carbonate (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 ° C for 1 h. Then slowly drop 4-trifluoromethylbenzyl bromide (618 μl, 4.00 mmol) and continue the reaction until the raw material 4 is completely reacted. After the reaction solution is cooled, add a large amount of water to dilute and adjust the solution pH to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.79 g of white solid with a yield of 76%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.67 (s, 4H), 7.45 (d, J = 5.3Hz, 2H), 7.17–7.09 (m, 2H), 4.65 (s, 2H).

[0122] Example 17 Synthesis of Intermediate 21

[0123] Synthesis of 2-((4-methylbenzyl)thio)-1H-benzo[d]imidazole (21)

[0124]

[0125] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly add 4-methylbenzyl bromide (560 μL, 4.01 mmol) and continue the reaction until the reaction of raw material 4 is complete by TLC. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the pH of the solution to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.81 g of white solid with a yield of 75%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 7.64–7.53 (m, 2H), 7.44 (dt, J = 7.4, 3.7Hz, 2H), 7.30 (d, J = 8.1Hz, 2H), 7.12 (m, 2H), 4.59 (s, 2H).

[0126] Example 18 Synthesis of Intermediate 22

[0127] Synthesis of 4-(((1H-benzo[d]imidazol-2-yl)thio)methyl)benzonitrile (22)

[0128]

[0129] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in N, N-dimethylformamide (2 mL). Add anhydrous sodium carbonate (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 ° C for 1 h. Then slowly add 4-bromomethylbenzonitrile (784 mg, 4.00 mmol) and continue stirring until the raw material 4 reacts completely. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the solution pH to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.56 g of white solid with a yield of 63%.

[0130] Example 19 Synthesis of Intermediate 23

[0131] Synthesis of 2-((Cyclopropylmethyl)thio)-1H-benzo[d]imidazole (23)

[0132]

[0133] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in DMF (2 mL). Add Na2CO3 (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 °C for 1 h. Then slowly add bromomethylcyclopropane (523 μl, 4.00 mmol) and continue stirring until the reaction of raw material 4 is complete. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the pH of the solution to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.45 g of white solid with a yield of 58%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 12.48 (s, 1H), 7.42 (d, J = 41.4Hz, 2H), 7.10 (dd, J = 6.0, 3.1Hz ,2H),3.29(d,J=7.3Hz,2H),2.21(m,1H),1.79(m,2H),1.69–1.42(m,4H),1.36–1.21(m,2H).

[0134] Example 20 Synthesis of Intermediate 24

[0135] Synthesis of 2-((Oxetane-3-ylmethyl)thio)-1H-benzo[d]imidazole (24)

[0136]

[0137] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in N, N-dimethylformamide (2 mL). Add anhydrous sodium carbonate (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 ° C for 1 h. Then slowly add 3-bromomethyloxetane (385 μL, 4.00 mmol) and continue stirring until the raw material 4 reacts completely. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the solution pH to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. The PE-EA system is pulped and purified to obtain 0.32 g of white solid with a yield of 44%.

[0138] Example 21 Synthesis of Intermediate 26

[0139] Synthesis of 4-(Bromomethyl)-N-(3-methoxypropyl)benzamide (26)

[0140]

[0141] Weigh 4-bromomethylbenzoic acid (1.0 g, 9.30 mmol) and dissolve it in anhydrous dichloromethane (10 mL). Add 3-methoxypropylamine (1.0 g, 11.16 mmol) and stir in a sand bath at 0°C for 20-30 min. Then slowly add DIPEA (4.24 g, 4.01 mmol) dropwise and continue the reaction for 1 h. After vacuum concentration, PE / EA system column chromatography purification was performed to obtain 2.26 g of a white solid with a yield of 85%.

[0142] Example 22 Synthesis of Intermediate 27

[0143] Synthesis of 2-((4-fluorobenzyl)sulfinyl)-1H-benzo[d]imidazole (27)

[0144]

[0145] Weigh the intermediate 5 (0.5 g, 1.94 mmol) and dissolve it in anhydrous tetrahydrofuran (5 mL). Stir in an ice bath for 30 min, then add OXONE (0.38 g, 1.26 mmol) aqueous solution in batches and keep stirring for 1 h. After the raw material reacts completely, dilute with a large amount of water, adjust the pH to 6-7 with saturated NaHCO3 solution, extract with EA, combine the organic phases, and wash with saturated NaCl solution. Concentrate under reduced pressure, purify with PE / EA system column chromatography, and dry in vacuo to obtain 0.28 g of white solid with a yield of 52%. 1 H NMR (300MHz, Chloroform-d) δ (ppm): 10.80 (s, 1H), 7.84 (s, 1H), 7.46 (s, 1H), 7.37 (p, J = 4.8, 3.8Hz, 2H), 7.04 (m, 2H), 6.90 (m, 2H), 4.58–4.26 (m, 2H).

[0146] Example 23 Synthesis of Intermediate 28

[0147] Synthesis of 2-((4-fluorobenzyl)sulfonyl)-1H-benzo[d]imidazole (28)

[0148]

[0149] Weigh the intermediate 5 (0.5 g, 1.94 mmol) and dissolve it in anhydrous tetrahydrofuran (5 mL). Stir at room temperature for 30 min, then add OXONE (0.76 g, 2.52 mmol) aqueous solution, and then keep stirring at room temperature overnight. After the raw material reacts completely, dilute with a large amount of water, adjust the pH to 6-7 with saturated NaHCO3 solution, extract with EA, combine the organic phases, and wash with saturated NaCl solution. Concentrate under reduced pressure, purify with PE / EA system column chromatography, and dry in vacuo to obtain 0.41 g of white solid with a yield of 73%. 1 H NMR (300MHz, DMSO-d6) δ (ppm) 13.79 (s, 1H), 7.70 (s, 2H), 7.39 (m, 2H), 7.27 (dd, J = 8.5, 5.6Hz, 2H), 7.14 (t, J = 8.7Hz, 2H), 5.00 (s, 2H).

[0150] Example 24 Synthesis of Intermediate 29

[0151] Synthesis of 2-((Cyclohexylmethyl)thio)-1H-benzo[d]imidazole (29)

[0152]

[0153] Weigh 2-mercaptobenzimidazole (0.5 g, 3.33 mmol) and dissolve it in N, N-dimethylformamide (2 mL). Add anhydrous sodium carbonate (705.65 mg, 6.66 mmol) and stir in a sand bath at 45 ° C for 1 h. Then slowly add bromocyclohexane (561.43 μL, 3.99 mmol) and continue stirring until the raw material 4 reacts completely. After the reaction solution is cooled, add a large amount of water to dilute it and adjust the solution pH to near neutral. At this time, a large amount of white flocculent precipitates are precipitated in the reaction. Purify it by PE-EA system column chromatography to obtain 0.401 g of white needle-shaped solid with a yield of 49%.

[0154] Example 25 Synthesis of Intermediate 31

[0155] Synthesis of 4-((2-chloro-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (31)

[0156]

[0157] Weigh 2-chlorobenzimidazole (2g, 13.31mmol) and dissolve it in anhydrous N,N-dimethylformamide (20ml). Add sodium hydroxide (1.05g, 7.51mmol) quickly under stirring at room temperature, then add intermediate 15 (3.00g, 10.49mmol), and keep stirring at room temperature for 24h. After the raw material reacts completely, dilute with a large amount of water, extract with EA three times, combine the organic phases, and wash with a saturated solution of NaCl. Concentrate under reduced pressure, purify with a PE / EA system column chromatography, and dry in vacuo to obtain 0.78g of a light yellow solid with a yield of 81%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.41 (t, J = 5.7Hz, 1H), 7.78 (d, J = 8.2Hz, 2H), 7.69–7.60 (m, 1H), 7.61–7.55 (m, 1H), 7.3 0–7.19(m,4H),5.58(s,2H),3.36(s,1H),3.31(d,J=6.5Hz,1H),3.28–3.22(m,2H),3.21(s,3H),1.72(p,J=6.6Hz,2H).

[0158] Example 26 Synthesis of Intermediate 33

[0159] Synthesis of 2-((4-fluorobenzyl)sulfonyl)-1H-benzo[d]imidazole (33)

[0160]

[0161] Weigh 2-aminobenzimidazole (0.5 g, 3.76 mmol) and dissolve it in anhydrous DMF (5 mL). Add triethylamine (0.76 g, 7.51 mmol) under stirring at room temperature, then slowly add 4-fluorobenzoyl chloride (1.19 g, 7.51 mmol) dropwise, and keep stirring at room temperature. After the raw material reacts completely, dilute with a large amount of water, extract with ethyl acetate three times, combine the organic phases, wash with a saturated solution of NaCl, and then dry with anhydrous sodium sulfate. Concentrate under reduced pressure and dry in vacuo to obtain 0.78 g of off-white solid with a yield of 81%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.26–8.17 (m, 2H), 8.05–7.96 (m, 1H), 7.45 (m, 2H), 7.32 (m, 3H), 7.14 (dd, J = 5.9, 3.2Hz, 2H).

[0162] Example 27 Synthesis of Intermediate 34

[0163] Synthesis of N-(1H-benzo[d]imidazol-2-yl)-4-fluorobenzenesulfonamide (34)

[0164]

[0165] Weigh 2-aminobenzimidazole (0.5 g, 3.76 mmol) and dissolve it in anhydrous dichloromethane (5 mL). Add 4-fluorobenzenesulfonyl chloride (0.876 g, 4.51 mmol) in an ice bath and stir for 10 min, then return to room temperature and stir overnight. After the reaction is complete, concentrate under reduced pressure, purify by PE / EA system column chromatography, and dry in vacuo to obtain 0.63 g of a white solid with a yield of 57%. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.04–7.97(m,2H),7.71(dd,J=8.3,1.1Hz,1H),7.30(dd,J=7.9,1.3Hz,1H),7.25–7.04(m,5H),6.13(s,2H).

[0166] Example 28 Synthesis of Intermediate 35

[0167] Synthesis of tert-butyl 4-(4-(bromomethyl)benzoyl)piperazine-1-carboxylate (35)

[0168]

[0169] Weigh 4-bromomethylbenzoic acid (1.0 g, 4.65 mmol) and dissolve it in anhydrous N, N-dimethylformamide (15 mL). Add 1-tert-butyloxycarbonylpiperazine (0.87 g, 4.65 mmol), HOBT (0.75 g, 5.58 mmol), and EDCI (1.07 g, 5.58 mmol) and stir at room temperature for 4-5 hours. After TLC monitoring, stop stirring after the reaction of the raw materials is complete. Dilute the reaction solution with a large amount of water, extract with EA 2-3 times, combine the organic phases, and wash with a saturated solution of NaCl. After vacuum concentration, PE / EA system column chromatography purification is performed to obtain 1.66 g of white solid with a yield of 93%.

[0170] Example 29 Synthesis of Intermediate 37

[0171] Synthesis of N-(4-(Hydroxymethyl)phenyl)acrylamide (37)

[0172]

[0173] Weigh 4-aminobenzyl alcohol (1.0 g, 8.12 mol) and dissolve it in anhydrous tetrahydrofuran (5 mL). Add N,N-diisopropylethylamine (3.15 g, 24.36 mmol) under ice bath conditions, then slowly add acryloyl chloride (808.38 mg, 8.93 mmol). After N2 replacement, keep ice bath for 20 min, then return to room temperature and stir for 4-5 h. After TLC monitoring, stop stirring after the reaction of the raw materials is complete, extract with DCM four times, combine the organic phases, wash with 1M NaOH solution and NaCl saturated solution, and dry with anhydrous magnesium sulfate. After reduced pressure concentration, PE / EA system column chromatography purification was obtained to obtain 0.71 g of white solid with a yield of 49.34%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 10.12 (s, 1H), 7.63 (d, J = 8.3Hz, 2H), 7.28 (d, J = 8.2Hz, 2H), 6.45 (dd, J = 17.0, 10.0 Hz,1H),6.26(dd,J=16.9,2.2Hz,1H),5.76(dd,J=10.0,2.2Hz,1H),5.14(t,J=5.7Hz,1H),4.46(d,J=5.7Hz,2H).

[0174] Example 30 Synthesis of Intermediate 38

[0175] Synthesis of N-(4-(bromomethyl)phenyl)acrylamide (38)

[0176]

[0177] Weigh the intermediate 37 (0.5 g, 2.82 mmol) and dissolve it in anhydrous dichloromethane (3 mL). Add triethylamine (0.43 g, 4.23 mmol) under ice bath conditions, then slowly add dichlorothionyl (402.79 mg, 3.39 mmol). Keep ice bath for 20 min and then return to room temperature and stir for 24 h. After TLC monitoring, stop stirring after the reaction of the raw materials is complete, concentrate under reduced pressure and purify by PE / EA system column chromatography to obtain 0.34 g of white solid, with a yield of 50%.

[0178] Example 31 Synthesis of Intermediate 39

[0179] Synthesis of N-(4-(Hydroxymethyl)phenyl)propionamide (39)

[0180]

[0181] Weigh 4-aminobenzyl alcohol (1.0 g, 8.12 mmol) and dissolve it in anhydrous tetrahydrofuran (5 mL). Add N,N-diisopropylethylamine (3.15 g, 24.36 mmol) under ice bath conditions, then slowly drop propionyl chloride (826.39 mg, 8.93 mmol). After N2 replacement, keep ice bath for 20 min, then return to room temperature and stir for 4-5 h. After TLC monitoring, stop stirring after the raw material reaction is complete, extract with DCM four times, combine the organic phases and wash with 1M NaOH solution and saturated brine successively, and dry over anhydrous sodium sulfate. After reduced pressure concentration, PE / EA system column chromatography purification is obtained to obtain 0.65 g of white solid with a yield of 45%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 9.80 (s, 1H), 7.53 (d, J = 8.4Hz, 2H), 7.21 (d, J = 8.3Hz, 2H), 5.08 (t, J =5.7Hz,1H),4.41(d,J=5.7Hz,2H),2.30(q,J=7.5Hz,2H),1.38–1.20(m,1H),1.07(t,J=7.5Hz,3H).

[0182] Example 32 Synthesis of Intermediate 40

[0183] Synthesis of N-(4-(bromomethyl)phenyl)propionamide (40)

[0184]

[0185] Intermediate 39 (0.5 g, 2.82 mmol) was weighed and dissolved in anhydrous dichloromethane (3 mL). Triethylamine (0.43 g, 4.23 mmol) was added under ice bath conditions, followed by slow dropwise addition of thionyl chloride (402.79 mg, 3.39 mmol). The mixture was kept in an ice bath for 20 min and then returned to room temperature and stirred for 24 h. Stirring was stopped after TLC monitoring that the raw material reaction was complete, and the mixture was concentrated under reduced pressure and purified by PE / EA system column chromatography to obtain 0.41 g of a white solid with a yield of 61%.

[0186] The following Examples 33-32 are the syntheses of the final products.

[0187] Example 33 Synthesis of Final Product JM-1

[0188] Synthesis of 4-((2-((cyclohexylmethyl)thio)-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-1)

[0189]

[0190] Weigh intermediate 3 (0.2 g, 0.81 mmol) and dissolve it in N, N-dimethylformamide (2 mL). Add NaOH (64.68 mg, 1.62 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (277.65 mg, 0.97 mmol) and stir at room temperature for 2-3 h until intermediate 3 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.25 g of white solid with a yield of 67%. mp166.6-167.1℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.44(t,J=5.6Hz,1H),8.21–8.14(m,1H),7.99–7.92(m,1H),7.79(d,J=8.1H z,2H),7.48(d,J=8.0Hz,2H),7.12(dd,J=7.6,6.4Hz,1H),5.79(s,2H),3.33(t,J=6.3Hz,2H),3.26(q,J=8.4 ,7.6Hz,2H),3.21(s,3H),3.17(d,J=6.8Hz,2H),1.83(d,J=12.3Hz,2H),1.74–1.69(m,2H),1.68–1.63(m,2H ),1.61–1.56(m,1H),1.26–1.17(m,1H),1.14(d,J=9.4Hz,2H),1.00(t,J=12.0Hz,2H).HRMS(ESI)calcd.for C 26 H 26 FN3O3[M+H] + 452.2246, found 453.2320.

[0191] Example 34 Synthesis of Final Product JM-2

[0192] Synthesis of 4-((2-((4-fluorobenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-2)

[0193]

[0194] Weigh intermediate 5 (0.2g, 0.77mmol) and dissolve it in anhydrous N,N-dimethylformamide (2ml), add NaOH (61.94mg, 1.55mmol) and stir at room temperature for 10min. Then add intermediate 26 (265.88mg, 0.93mmol) and stir at room temperature for 2-3h until intermediate 5 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.25g of white solid, yield 67%. mp158.6-159.6℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.40(t,J=5.6Hz,1H),7.72(d,J=8.0Hz,2H),7.65–7.58(m,1H),7.48(m,3H),7.18(d,J=6.2Hz,2H),7.15(d,J= 2.0Hz,2H),7.11(d,J=8.9Hz,2H),5.41(s,2H),4.62(s,2H),3.33(d,J=6.2Hz,2H),3.25(t,J=6.5Hz,2H),3.21(s,3H),1.71(p,J=6.7Hz,2H). 13 C NMR(101MHz,DMSO-d6)δ(ppm):166.22,161.94(d, 1 J C-F =244.4Hz),151.50,143.42,139.68,136.62,134.39(d, 4 J C-F =3.0Hz),131.47(d, 3 J C-F =9.1Hz),128.00,127.21,122.36,118.34,115.74(d, 2 J C-F =21.3Hz),110.36,70.14,58.36,46.84,36.96,35.42,29.66.HRMS(ESI)calcd.for C 26 H 32 N4O2S[M+H] + 463.1730, found 464.1800.

[0195] Example 35 Synthesis of Final Product JM-3

[0196] Synthesis of 4-((2-((cyclohexylmethyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-3)

[0197]

[0198] Weigh intermediate 6 (0.2g, 0.81mmol) and dissolve it in anhydrous N,N-dimethylformamide (2ml), add NaOH (64.94mg, 1.62mmol) and stir at room temperature for 10min. Then add intermediate 26 (278.77mg, 0.97mmol) and stir at room temperature for 2-3h until intermediate 6 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.18g of white solid, yield 49%. mp143.2-144.7℃. 1 H NMR(300MHz,DMSO-d6)δ(ppm):8.41(t,J=5.7Hz,1H),7.77(d,J=8.2Hz,2H),7.63–7.53(m,1H),7.51– 7.40(m,1H),7.22(d,J=8.1Hz,2H),7.18–7.13(m,2H),5.45(s,2H),3.32(d,J=6.3Hz,2H),3.26(d,J=6 .7Hz,4H),3.21(s,3H),1.80(s,1H),1.78–1.73(m,2H),1.71(s,1H),1.70–1.63(m,2H),1.62(d,J=7.9 Hz,1H),1.57(dd,J=6.9,3.4Hz,1H),1.31–1.19(m,1H),1.13(d,J=9.6Hz,2H),0.98(q,J=11.7Hz,2H). 13 C NMR(101MHz,DMSO-d6)δ(ppm):166.20,152.42,143.47,139.82,136.67,134.50,128.03,127.20,122.1 6,118.17,110.14,70.15,58.36,46.79,37.62,36.97,32.29,29.68,26.23,25.88.HRMS(ESI)calcd.for C 26 H 33 N3O2S[M+H] + 451.2293, found 452.2372.

[0199] Example 36 Synthesis of Final Product JM-4

[0200] Synthesis of 4-((2-((cyclohexylmethyl)thio)-1H-imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-4)

[0201]

[0202] Weigh intermediate 8 (0.2 g, 1.02 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (81.50 mg, 2.04 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (437.32 mg, 1.53 mmol) and stir at room temperature for 2-3 h until intermediate 8 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.18 g of white solid with a yield of 44%. mp123.5-125.1℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.47 (t, J = 5.6 Hz, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.36 (d, J=1.4Hz,1H),7.19(d,J=8.1Hz,2H),7.00(d,J=1.3Hz,1H),5.22(s,2H),3.34(t,J=6. 3Hz,2H),3.28(d,J=6.3Hz,2H),3.22(s,3H),2.84(d,J=6.8Hz,2H),1.73(p,J=6.3Hz, 3H),1.68–1.55(m,4H),1.37(m,1H),1.19–1.00(m,3H),0.85(q,J=11.6,10.8Hz,2H). 13 CNMR(75MHz,DMSO-d6)δ(ppm):166.18,141.28,140.69,134.35,129.40,127.95,127.27,122.8 4,70.18,58.36,49.25,41.03,37.64,36.99,32.20,29.70,26.27,25.88.HRMS(ESI)calcd.for C 22 H 32 N3O2S[M+H] + 401.2137, found402.2219.

[0203] Example 37 Synthesis of Final Product JM-5

[0204] Synthesis of (4-((2-((cyclohexylmethyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)(piperazin-1-yl)methanone (JM-5)

[0205]

[0206] Weigh intermediate 9 (0.2g, 0.74mmol) and dissolve it in anhydrous N,N-dimethylformamide (2mL), add NaOH (59.44mg, 1.49mmol) and stir at room temperature for 10min. Add intermediate 35 (284.80mg, 0.74mmol) and stir at room temperature for 2-3h until intermediate 3 and 9 react completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined and washed with saturated brine, and dried over anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Then add HCl / EA (15mL), stir overnight at room temperature, spin dry the solvent, dissolve with an appropriate amount of water, and adjust the solution with saturated sodium bicarbonate solution until a large amount of white solid precipitates. 0.13g of white solid is obtained, with a yield of 38%. mp129.1-129.7℃. 1 H NMR(300MHz,DMSO-d6)δ(ppm):7.48–7.39(m,2H),7.37–7.24(m,3H),7.20–7.11(m,2H),7.07–6.99 (m,3H),5.05(s,2H),4.16(s,2H),3.50(s,2H),3.16(s,2H),2.76–2.53(m,4H),1.35–1.18(m,1H).

[0207] Example 38 Synthesis of Final Product JM-6

[0208] Synthesis of 4-((3-(4-fluorobenzyl)-2-carbonyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-6)

[0209]

[0210] Weigh intermediate 12 (0.2 g, 0.83 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (49.35 mg, 1.24 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (236.26 mg, 0.83 mmol) and stir at room temperature for 2-3 h until intermediate 12 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.21 g of white solid with a yield of 57%. mp147.5-149.5℃. 1 H NMR (400MHz, DMSO-d6) δ (ppm): 8.41 (t, J = 5.7Hz, 1H), 7.81–7.75 (m, 2H), 7.44–7.35 (m, 4H), 7.22–7.14 (m, 3H), 7.1 2–7.07(m,1H),7.04–6.95(m,2H),5.14(s,2H),5.10(s,2H),3.30–3.24(m,2H),3.22(s,3H),1.72(p,J=6.6Hz,2H). 13 CNMR(75MHz,DMSO-d6)δ(ppm):166.44,162.09(d, 1 J C-F =242.2Hz),154.32,140.47,134.55,133.80(d, 4 J C-F =3.3Hz),130.08(d, 3 J C-F =8.3Hz),129.28,128.12,127.72,121.85,116.04(d, 2 J C-F =21.0Hz),108.97,70.29,58.45,44.16,43.72,37.11,29.79.HRMS(ESI)calcd.for C 26 H 26 FN3O2[M+H] + 447.1958, found 448.2041.

[0211] Example 39 Synthesis of Final Product JM-7

[0212] Synthesis of 1-(4-fluorobenzyl)-3-(4-(piperazine-1-carbonyl)benzyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (JM-7)

[0213]

[0214] Weigh intermediate 12 (0.2 g, 0.83 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (66.04 mg, 1.65 mmol) and stir at room temperature for 10 min. Then add intermediate 35 (316.43 mg, 0.83 mmol) and stir at room temperature for 2-3 h until intermediate 12 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.15 g of white solid with a yield of 42%. 1 H(300MHz,DMSO-d6)δ(ppm):7.40(dd,J=8.3,5.4Hz,3H),7.35(d,J=1.8Hz,3H),7.18(d,J=8.7Hz,2H),7.16–7.11(m,2H ),7.01(dd,J=5.8,3.2Hz,2H),5.13(s,2H),5.09(s,2H),3.50(s,2H),3.20(s,2H),2.62(s,4H),1.24(d,J=6.9Hz,1H).

[0215] Example 40 Synthesis of Final Product JM-8

[0216] Synthesis of 1-((4-fluorophenyl)sulfonyl)-3-(4-nitrobenzyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (JM-8)

[0217]

[0218] Weigh the intermediate 14 (0.2g, 0.68mmol) and dissolve it in anhydrous N,N-dimethylformamide (2mL), add NaOH (54.74mg, 1.37mmol) and stir at room temperature for 10min. Then add 4-nitrobenzyl bromide (177.39mg, 0.82mmol) and stir at room temperature for 2-3h until the intermediate 14 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, and the organic phases are combined, washed with saturated brine, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.21g of white solid with a yield of 72%. mp133.4-133.2℃. 1HNMR (300MHz, DMSO-d6) δ (ppm): 8.20–8.07 (m, 4H), 7.88–7.81 (m, 1H), 7.58–7.48 (m, 2H), 7.47–7.41 (m, 2H), 7.22 (dd, J = 4.3, 2.3Hz, 3H), 5.14 (s, 2H). 13 C NMR(101MHz,DMSO-d6)δ(ppm):166.27(d, 4 J C-F =255.5Hz),143.82,134.86,133.65(d, 4 J C-F =3.0Hz),131.36(d, 3 J C-F =11.1Hz),128.81,128.32,125.65,125.36,124.33,123.50,119.81,117.65(d, 2 J C-F =9.1Hz),114.96,114.75,113.15,110.02,43.90.HRMS(ESI)calcd.for C 20 H 14 N3O5S[M+H] + 427.0638,found428.0718.

[0219] Example 41 Synthesis of Final Product JM-9

[0220] Synthesis of 1-((4-fluorophenyl)sulfonyl)-3-(4-methylbenzyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (JM-9)

[0221]

[0222] Weigh the intermediate 14 (0.2 g, 0.68 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (54.74 mg, 1.37 mmol) and stir at room temperature for 10 min. Then add 4-methylbenzyl bromide (151.96 mg, 0.82 mmol) and stir at room temperature for 2-3 h until the intermediate 14 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.15 g of white solid with a yield of 55%. mp127.5-128.5℃. 1H NMR(300MHz,DMSO-d6)δ(ppm):8.16–8.08(m,2H),7.86–7.79(m,1H),7.59–7.46 (m,2H),7.19(dq,J=4.8,2.9,2.4Hz,3H),7.06(s,4H),4.92(s,2H),2.22(s,3H).

[0223] Example 41 Synthesis of Final Product JM-10

[0224] Synthesis of 1-Benzyl-3-((4-fluorophenyl)sulfonyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (JM-10)

[0225]

[0226] Weigh the intermediate 14 (0.2 g, 0.68 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (54.74 mg, 1.37 mmol) and stir at room temperature for 10 min. Then add benzyl bromide (140.44 mg, 0.82 mmol) and stir at room temperature for 2-3 h until the intermediate 14 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA three times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.18 g of white solid with a yield of 69%. mp158.6-159.6℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.13 (m, 2H), 7.83 (m, 1H), 7.58–7.46 (m, 2H), 7.28–7.19 (m, 6H), 7.18–7.12 (m, 2H), 4.98 (s, 2H). 13 CNMR(101MHz,DMSO-d6)δ(ppm):164.98,150.62,136.11,133.66(d, 4 J C-F =3.0Hz),131.34(d, 3 J C-F =10.3Hz),129.77,129.16,128.23,127.65,125.55,125.31,123.31,117.62(d, 2 J C-F =23.3Hz),113.10,110.15,44.34.HRMS(ESI)calcd.for C 20 H 15 N2O3S[M+H] +382.0787, found 383.0858.

[0227] Example 42 Synthesis of Final Product JM-11

[0228] Synthesis of 1-(4-fluorobenzyl)-3-((4-fluorophenyl)sulfonyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (JM-11)

[0229]

[0230] Weigh the intermediate 14 (0.2 g, 0.68 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (54.74 mg, 1.37 mmol) and stir at room temperature for 10 min. Then add 4-methylbenzyl bromide (155.21 mg, 0.82 mmol) and stir at room temperature for 2-3 h until the intermediate 14 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA three times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.15 g of white solid with a yield of 54%. mp137.1-137.5℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.16–8.09 (m, 2H), 7.82 (dd, J = 6.1, 2.4Hz, 1H) ,7.53(t,J=8.8Hz,2H),7.29–7.19(m,5H),7.12(t,J=8.8Hz,2H),4.96(s,2H). 13 C NMR(101MHz,DMSO-d6)δ(ppm):167.27(d, 1 J C-F =255.5Hz),143.82,133.65(d, 4 J C-F =3.1Hz),131.36(d, 3 J C-F =10.2Hz),128.81,128.32(d, 3 J C-F =8.5Hz),125.65,125.36,124.33,123.50,119.81,117.65(d, 2 J C-F =23.2Hz),114.96,114.85(d, 2 J C-F =21.5Hz),113.15,110.02,43.90.HRMS(ESI)calcd.for C20 H 14 F2N2O3S[M+H] + 400.0693, found 401.0758.

[0231] Example 43 Synthesis of Final Product JM-12

[0232] Synthesis of 4-((3-((4-fluorophenyl)sulfonyl)-2-carbonyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-12)

[0233]

[0234] Weigh intermediate 14 (0.2 g, 0.68 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (54.74 mg, 1.37 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (234.98 mg, 0.82 mmol) and stir at room temperature for 2-3 h until intermediate 14 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, and the organic phases are combined, washed with saturated brine, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.1 g of white solid with a yield of 30%. mp160.3-161.2℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.40(d,J=6.0Hz,1H),8.18–8.09(m,2H),7.88–7.79(m,1H),7.72(d,J=8.3Hz,2H),7.53(t,J =8.8Hz,2H),7.21(m,5H),5.03(s,2H),3.36(s,1H),3.32(s,1H),3.27(t,J=6.5Hz,2H),3.21(s,3H),1.71(p,J=6.6Hz,2H). 13 C NMR(75MHz,DMSO-d6)δ(ppm):165.86,165.59(d, 1 J C-F =252.8Hz),150.26,138.67,134.29,133.36(d, 4 J C-F =2.3Hz),131.02(d, 3 J C-F =9.8Hz),129.35,127.68,127.16,125.10,123.02,117.30(d, 2 JC-F =23.3Hz),112.76,109.77,69.82,58.02,43.79,36.64,29.32.HRMS(ESI)calcd.for C 25 H 24 FN3O5S[M+H] + 497.1421, found 498.1499.

[0235] Example 44 Synthesis of Final Product JM-13

[0236] Synthesis of N-(3-methoxypropyl)-4-((2-((4-methylbenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)benzamide (JM-13)

[0237]

[0238] Weigh intermediate 15 (0.2 g, 0.73 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (58.23 mg, 1.46 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (249.96 mg, 0.87 mmol) and stir at room temperature for 2-3 h until intermediate 15 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.27 g of white solid with a yield of 77%. mp155.3-156.0℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.41(t,J=5.6Hz,1H),7.71(d,J=8.0Hz,2H),7.64–7.59(m,1H),7.49–7.43(m,3H),7.35(d,J=8.3Hz ,2H),7.20–7.11(m,4H),5.41(s,2H),4.61(s,2H),3.32(d,J=6.2Hz,2H),3.25(d,J=6.4Hz,2H),3.21(s,3H),1.71(p,J=6.6Hz,2H). 13C NMR(75MHz,DMSO-d6)δ(ppm):165.35,150.78,142.59,138.79,136.28,135.67,133.69 128.54,127.10,126.32,121.42,117.43,109.43,69.26,57.47,45.94,36.07,35.35,28.79,20.27.HRMS(ESI)calcd.forC 26 H 26 ClN3O2S[M+H] + 479.1434, found 480.1514.

[0239] Example 45 Synthesis of Final Product JM-14

[0240] Synthesis of 4-((2-((4-bromobenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-14)

[0241]

[0242] Weigh intermediate 16 (0.2 g, 0.63 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (50.12 mg, 1.25 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (215 mg, 0.75 mmol) and stir at room temperature for 2-3 h until intermediate 16 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.26 g of white solid with a yield of 78%. mp147.7-148.9℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.39 (s, 1H), 7.72 (m, 2H), 7.61 (d, J = 7.2Hz, 1H), 7.48 (m, 3H), 7.43 –7.35(m,2H),7.22–7.09(m,4H),5.41(s,2H),4.60(s,2H),3.35–3.17(m,7H),1.77–1.65(m,2H). 13C NMR(75MHz,DMSO-d6)δ(ppm):166.17,151.30,143.35,139.58,137.10,136.57,134.52,132.46,131.21,128. 82,127.95,127.13,122.32,118.29,110.30,70.08,58.30,46.79,36.90,35.35,29.61.HRMS(ESI)calcd.for C 26 H 26 BrN3O2S[M+H] + 523.0929, found 524.1003.

[0243] Example 46 Synthesis of Final Product JM-15

[0244] Synthesis of 4-((2-(Benzylthio)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-15)

[0245]

[0246] Weigh intermediate 17 (0.2 g, 0.83 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (66.57 mg, 1.66 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (285.78 mg, 0.99 mmol) and stir at room temperature for 2-3 h until intermediate 17 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.31 g of white solid with a yield of 84%. mp143.1-145.0℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.41(t,J=5.7Hz,1H),7.72(d,J=8.3Hz,2H),7.65–7.58(m,1H),7.45(m,3H),7.34 –7.24(m,3H),7.21–7.11(m,4H),5.41(s,2H),4.62(s,2H),3.33–3.22(m,4H),3.21(s,3H),1.71(p,J=6.6Hz,2H). 13CNMR(75MHz,DMSO-d6)δ(ppm):166.32,152.44,143.62,128.14,127.29,122.28,118.28 ,110.27,70.26,58.47,46.90,38.10,37.08,32.23,29.79,25.35.HRMS(ESI)calcd.for C 26 H 27 N3O2S[M+H] + 445.1824, found 446.1905.

[0247] Example 47 Synthesis of Final Product JM-16

[0248] Synthesis of N-(3-methoxypropyl)-4-((2-((4-methylbenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)benzamide (JM-16)

[0249]

[0250] Weigh intermediate 18 (0.2 g, 0.79 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (62.90 mg, 1.57 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (270 mg, 0.94 mmol) and stir at room temperature for 2-3 h until intermediate 18 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.30 g of white solid with a yield of 83%. mp147.5-148.8℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.38(t,J=5.6Hz,1H),7.70(d,J=8.0Hz,2H),7.64–7.58(m,1H),7.48–7.41(m,1H),7.31(d,J=7.8Hz,2H ),7.21–7.14(m,3H),7.14–7.05(m,3H),5.40(s,2H),4.57(s,2H),3.32-3.22(m,4H),3.21(s,3H),2.26(s,3H),1.71(p,J=6.6Hz,2H). 13C NMR(75MHz,DMSO-d6)δ(ppm):166.09,151.49,143.32,139.55,137.63,136.48,134.42,129.32,128.84, 127.85,127.10,122.21,118.20,110.21,70.03,58.24,46.73,36.85,36.23,29.55.HRMS(ESI)calcd.for C 27 H 29 N3O2S[M+H] + 459.1980, found 460.2049.

[0251] Example 48 Synthesis of Final Product JM-17

[0252] Synthesis of 4-((2-((4-methoxybenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-17)

[0253]

[0254] Weigh intermediate 19 (0.2 g, 0.74 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (59.18 mg, 1.48 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (254.04 mg, 0.89 mmol) and stir at room temperature for 2-3 h until intermediate 19 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.26 g of white solid with a yield of 74%. mp151.1-152.5℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.39(t,J=5.6Hz,1H),7.72(d,J=8.0Hz,2H),7.66–7.59(m,1H),7.45(m,1H),7.40–7.32(m,2H),7.23–7.10(m,4 H),6.91–6.81(m,2H),5.40(s,2H),4.57(s,2H),3.71(s,3H),3.33(d,J =6.3Hz,2H),3.26(t,J=6.6Hz,2H),3.21(s,3H),1.72(p,J=6.6Hz,2H). 13C NMR(75MHz,DMSO-d6)δ(ppm):166.35,164.78,161.51,147.18,141.11,139.48,135.74,134.78,134.28,128.08,127.11, 126.75,124.94,123.83,121.82,116.30,116.02,112.97,70.28,60.09,58.50,48.15,37.10,29.80.HRMS(ESI)calcd.for C 27 H 29 N3O3S[M+H] + 475.1930, found 476.2008.

[0255] Example 49 Synthesis of Final Product JM-18

[0256] Synthesis of N-(3-methoxypropyl)-4-((2-((4-(trifluoromethyl)benzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)benzamide (JM-18)

[0257]

[0258] Weigh the intermediate 20 (0.2g, 0.86mmol) and dissolve it in anhydrous N,N-dimethylformamide (2mL), add NaOH (68.86mg, 1.72mmol) and stir at room temperature for 10min. Then add the intermediate 26 (295.60mg, 1.03mmol) and stir at room temperature for 2-3h until the intermediate 20 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.20g of white solid, yield 60%. mp172.3-172.9℃. 1 H NMR(300MHz, DMSO-d6)δ(ppm):8.43(t,J=5.6Hz,1H),7.72(d,J=8.3Hz,2H),7.66(s,4H),7.64–7.59(m,1H),7.52–7.43(m,1H) ,7.24–7.11(m,4H),5.43(s,2H),4.71(s,2H),3.33(t,J=6.3Hz,2H),3.26(q,J=6.7Hz,2H),3.21(s,3H),1.71(p,J=6.6Hz,2H). 13C NMR (75MHz, DMSO) δ (ppm): 166.92, 151.89, 144.05, 143.82, 140.31, 137.38, 135.28, 130.87, 128.70, 127.88, 126.47 (q, 4 J C-F =3.75Hz),123.10(q, 3 J C-F =10.5Hz),119.05,111.07,70.81,59.04,47.54,41.44,41.17,40.89,40.61,40.33,40.05,39.78,37.64,36.07,30.35.HRMS(ESI)calcd.forC 27 H 26 F3N3O2S[M+H] + 513.1698, found 514.1771.

[0259] Example 50 Synthesis of Final Product JM-19

[0260] Synthesis of N-(3-methoxypropyl)-4-((2-((4-(trifluoromethoxy)benzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)benzamide (JM-19)

[0261]

[0262] Weigh the intermediate 21 (0.2 g, 0.62 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (49.33 mg, 1.23 mmol) and stir at room temperature for 10 min. Then add the intermediate 26 (211.77 mg, 0.74 mmol) and stir at room temperature for 2-3 h until the intermediate 21 reacts completely. After stopping stirring, dilute the reaction solution with a large amount of water, extract EA 3 times, combine the organic phases, wash with a saturated solution of NaCl, and then dry with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.23 g of white solid with a yield of 70%. mp173.9-175.5℃. 1H NMR(300MHz, DMSO-d6)δ(ppm):8.41(t,J=5.6Hz,1H),7.73(d,J=8.1Hz,2H),7.66–7.60(m,1H),7.60–7.55(m,2H),7.51–7.44(m,1H),7 .33–7.25(m,2H),7.18(m,4H),5.42(s,2H),4.66(s,2H),3.34(t,J=6.3Hz,2H),3.31–3.23(m,2H),3.21(s,3H),1.72(p,J=6.6Hz,2H). 13 C NMR (75MHz, DMSO-d6) δ (ppm): 165.59, 150.74, 147.36, 142.74, 138.97, 136.96, 136.03, 133.94, 130.67, 127. 35,126.54,121.72,120.83,117.68,109.68,69.48,57.67,46.19,36.30,34.54,29.00.HRMS(ESI)calcd.for C 27 H 26 F3N3O3S[M+H] + 529.1647, found 530.1716.

[0263] Example 51 Synthesis of Final Product JM-20

[0264] Synthesis of 4-((2-((4-cyanobenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-20)

[0265]

[0266] Weigh the intermediate 22 (0.2 g, 0.75 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (60.30 mg, 1.72 mmol) and stir at room temperature for 10 min. Then add the intermediate 26 (258.85 mg, 0.90 mmol) and stir at room temperature for 2-3 h until the intermediate 22 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.12 g of white solid, yield 34%. mp157.1-157.7℃. 1H NMR (300MHz, DMSO-d6) δ (ppm): 8.41 (t, J = 5.6 Hz, 1H), 7.75 (t, J = 7.8 Hz, 4H), 7.63 (m, 3H), 7.47 (m, 1H), 7.17 (m, 4H), 5.42 (s, 2H), 4.70 (s, 2H), 3.34 (t, J = 6.3Hz, 2H), 3.27 (q, J = 6.8Hz, 2H), 3.21 (s, 3H), 1.72 (p, J = 6.6Hz, 2H). 13 C NMR(75MHz,DMSO-d6)δ(ppm):165.79,150.65,143.73,139.18,136.29,134.16,132.38,129.93,127.59, 126.76,122.01,118.74,117.95,110.05,69.72,57.93,46.44,36.55,35.11,29.24.HRMS(ESI)calcd.for C 27 H 26 N4O2S[M+H] + 470.1776,found471.1851.

[0267] Example 52 Synthesis of Final Product JM-21

[0268] Synthesis of 4-((2-((cyclopentylmethyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-21)

[0269]

[0270] Weigh the intermediate 23 (0.2g, 0.86mmol) and dissolve it in anhydrous N,N-dimethylformamide (2mL), add NaOH (68.86mg, 1.72mmol) and stir at room temperature for 10min. Then add the intermediate 26 (295.60mg, 1.03mmol) and stir at room temperature for 2-3h until the intermediate 23 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.19g of white solid, yield 50%. mp159.1-140.3℃. 1H NMR (300MHz, DMSO-d6) δ (ppm): 8.45 (d, J = 6.1 Hz, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 6 .8Hz,1H),7.45(d,J=7.4Hz,1H),7.22(d,J=7.9Hz,2H),7.18–7.09(m,2H),5.45(s,2H), 3.31(s,2H),3.26(d,J=6.5Hz,2H),3.21(d,J=1.4Hz,3H),2.22(p,J=7.6Hz,1H),1.73(s ,2H),1.70(d,J=6.5Hz,2H),1.64–1.54(m,2H),1.50(d,J=8.0Hz,2H),1.32–1.21(m,2H). 13 C NMR (75MHz, DMSO-d6) δ (ppm): 166.44, 154.32, 140.47, 134.55, 133.82, 130.08, 129.28, 128.12, 127. 72,121.85,116.18,115.90,108.97,70.29,58.45,44.16,43.72,37.11,29.79.HRMS(ESI)calcd.forC 25 H 31 N3O2S[M+H] + 437.2137, found 438.2207.

[0271] Example 53 Synthesis of Final Product JM-22

[0272] Synthesis of N-(3-methoxypropyl)-4-((2-((4-(trifluoromethoxy)benzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)benzamide (JM-22)

[0273]

[0274] Weigh intermediate 24 (0.2 g, 0.67 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (53.98 mg, 1.35 mmol) and stir at room temperature for 10 min. Then add intermediate 26 (231.73 mg, 0.81 mmol) and stir at room temperature for 2-3 h until intermediate 24 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.19 g of white solid with a yield of 66%. mp138.2-140.1℃. 1H NMR (300MHz, DMSO-d6) δ (ppm): 8.42 (t, J = 5.6 Hz, 1H), 7.76 (d, J = 8.0 Hz, 2H), 7. 63–7.55(m,1H),7.47(m,1H),7.25–7.12(m,4H),5.44(s,2H),4.62(dd,J=7.8, 6.0Hz,2H),4.34(t,J=6.1Hz,2H),3.67(d,J=7.5Hz,2H),3.41-3.38(m,1H),3. 33(d,J=6.1Hz,2H),3.27(t,J=6.5Hz,2H),3.21(s,3H),1.71(p,J=6.6Hz,2H).

[0275] Example 53 Synthesis of Final Product JM-23

[0276] 4-((2-(Benzylsulfinyl)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide

[0277]

[0278] Weigh the intermediate 27 (0.2g, 0.78mmol) and dissolve it in anhydrous N,N-dimethylformamide (2mL), add NaOH (62.42mg, 1.56mmol) and stir at room temperature for 10min. Then add the intermediate 26 (267.95mg, 0.94mmol), keep stirring at room temperature for 2-3h until the raw material reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and dried with anhydrous Na2SO4. Purify by PE-EA system column chromatography. Obtain 0.14g of white solid, yield 39%. mp143.5-145.0℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.41 (d, J = 6.2 Hz, 1H), 7.85 (dd, J = 7.1, 4.0 Hz, 1 H),7.69(d,J=8.4Hz,2H),7.54(m,1H),7.34(m,2H),7.26(d,J=6.0Hz,2H),7.1 2(d,J=8.2Hz,4H),5.74–5.51(m,2H),4.86–4.63(m,2H),3.29(s,2H),3.25(d, J=6.9Hz,2H),3.20(d,J=3.2Hz,3H),1.77–1.65(m,2H).HRMS(ESI)calcd.forC 26 H 26 FN3O4S[M+H] +479.1697, found 480.1760.

[0279] Example 54 Synthesis of Final Product JM-24

[0280] Synthesis of 4-((2-(Benzylsulfinyl)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-24)

[0281]

[0282] Weigh the intermediate 28 (0.2g, 0.73mmol) and dissolve it in anhydrous N,N-dimethylformamide (2mL), add NaOH (58.75mg, 1.47mmol) and stir at room temperature for 10min. Then add the intermediate 26 (252.20mg, 0.88mmol), keep stirring at room temperature for 2-3h until the raw material reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.15g of white solid, yield 43%. mp151.1-152.0℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.40 (t, J = 5.7Hz, 1H), 7.92 (m, 1H), 7.69 (dd, J = 8 .4,2.3Hz,2H),7.62–7.55(m,1H),7.47–7.39(m,2H),7.34(m,2H),7.19(m,2H),7 .11–7.01(m,2H),5.71–5.62(m,2H),5.13(d,J=2.2Hz,2H),3.32(dd,J=6.3,2.3H z, 2H), 3.25 (d, J = 6.8Hz, 2H), 3.20 (d, J = 2.4Hz, 3H), 1.69 (td, J = 7.8, 5.7Hz, 2H). 13 C NMR(75MHz,DMSO-d6)δ(ppm):166.26,147.08,141.00,139.37,135.62,134.67,134.17(q, 3 J C-F =8.3Hz),127.97,127.00,126.65,124.83,123.72,121.70,116.04(d, 2 J C-F=21.8Hz),112.85,70.17,59.99,58.38,48.06,37.00,29.68.HRMS(ESI)calcd.for C 26 H 26 FN3O4S[M+H] + 495.1628, found 496.1707.

[0283] Example 55 Synthesis of Final Product JM-25

[0284] Synthesis of 4-((2-(cyclohexylamino)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-25)

[0285]

[0286] Weigh the intermediate 30 (0.2g, 0.86mmol) and dissolve it in anhydrous N,N-dimethylformamide (2mL). Add NaOH (68.86mg, 1.72mmol) and stir at room temperature for 10min. Then add the intermediate 26 (295.60mg, 1.03mmol) and stir at room temperature for 2-3h until the raw material reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.16g of white solid, yield 43%. mp143.0-145.0℃. 1 H NMR(300MHz,DMSO-d6)δ(ppm):8.43(t,J=5.6Hz,1H),7.83–7.74(m,2H),7.66–7.57(m,1 H),7.51–7.42(m,1H),7.27–7.11(m,4H),5.47(s,2H),3.99–3.86(m,1H),3.35(d,J=6.4 Hz,2H),3.28(d,J=6.4Hz,2H),3.23(d,J=1.2Hz,3H),2.11(d,J=12.2Hz,2H),1.74(p,J= 7.8,7.4Hz,4H),1.62–1.44(m,4H),1.40(s,1H),1.37–1.21(m,2H).HRMS(ESI)calcd.for C 25 H 31 N3O2S[M+H] + 437.2137, found 438.2214.

[0287] Example 56 Synthesis of Final Product JM-26

[0288] Synthesis of 4-((2-((4-fluorophenyl)amino)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-26)

[0289]

[0290] Weigh the intermediate 31 (0.2 g, 0.56 mmol), add 4-fluoroaniline (186.32 mg, 1.68 mmol) under N2 protection, heat and stir at 160°C for 16 h until the raw material reacts completely. After the reaction solution is cooled, add an appropriate amount of EA to precipitate a large amount of light blue solid. Filter the solid, dissolve it in DCM, and purify it by DCM-MeOH column chromatography. Obtain 0.12 g of blue solid, with a yield of 52%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 9.13 (d, J = 3.1 Hz, 1H), 8.36 (s, 1H), 7.90 (p, J =3.9Hz,2H),7.76(m,2H),7.39(d,J=7.7Hz,1H),7.22(d,J=10.4Hz,2H),7.16 (m,2H),7.04(t,J=5.0Hz,1H),6.98(d,J=7.2Hz,1H),5.58(d,J=3.1Hz,2H), 3.32(t,2H),3.25(d,J=6.2Hz,2H),3.21(d,J=3.3Hz,3H),1.73–1.67(m,2H). 13 C NMR(75MHz,DMSO-d6)δ(ppm):166.61,151.07,142.61,140.67,137.92,134.64,134.23,128.27,127.20,121.91,120.35(d, 3 J C-F =6.8Hz),117.04,115.85(q, 2 J C-F =21.8Hz),109.33,70.43,58.60,45.43,37.25,29.93.HRMS(ESI)calcd.for C 25 H 25 FN4O2[M+H] + 432.1962, found 433.2038.

[0291] Example 57 Synthesis of Final Product JM-27

[0292] Synthesis of 4-((2-(cyclohexylamino)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-27)

[0293]

[0294] Weigh the intermediate 31 (0.2 g, 0.56 mmol), add cyclohexylamine (277.16 mg, 2.79 mmol) under N2 protection, heat and stir at 160°C for 16 h until the raw material reacts completely. After stopping stirring, the reaction solution is cooled to room temperature, diluted with a large amount of water, washed with 1N hydrochloric acid, extracted with EA three times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate, and purified by DCM-MeOH column chromatography. 0.1 g of brown solid is obtained, with a yield of 42%. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.38 (t, J = 5.7Hz, 1H), 7.75 (d, J = 8.1Hz, 2H), 7.23–7.15 (m, 3H), 6.98 (d, J = 7.7Hz, 1H), 6.95 (s, 1H), 6.80 (t, J = 7.5Hz,1H),6.58(d,J=7.8Hz,1H),5.33(s,2H),3.34–3.23(m,6H),3.2 1(s,3H),1.99(d,J=10.0Hz,2H),1.78–1.57(m,7H),1.38–1.20(m,6H). 13 C NMR(75MHz,DMSO-d6)δ(ppm):165.73,154.01,142.74,140.13,134.18,133.55,127.23,126.44,120.34,11 8.08,114.75,107.55,69.56,57.73,51.37,43.94,36.36,32.72,29.06,25.30,24.83.HRMS(ESI)calcd.for C 25 H 32 ClN4O2[M+H] + 420.2525, found 421.2603.

[0295] Example 58 Synthesis of Final Product JM-28

[0296] Synthesis of 4-((2-(Benzylsulfinyl)-1H-benzo[d]imidazol-1-yl)methyl)-N-(3-methoxypropyl)benzamide (JM-28)

[0297]

[0298] Weigh the intermediate 33 (0.2 g, 0.84 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (67.43 mg, 1.69 mmol) and stir at room temperature for 10 min. Then add the intermediate 26 (289.47 mg, 1.01 mmol) and keep stirring at room temperature for 2-3 h until the raw material reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and then dried with anhydrous sodium sulfate. Purify by PE-EA system column chromatography. Obtain 0.19 g of white solid, yield 51%. mp184.2-185.3℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 12.84 (s, 1H), 8.38 (t, J = 5.6Hz, 1H), 8.30 (m, 2H), 7.78 (d, J = 8.0Hz, 2H), 7.58–7.53 (m, 1H), 7.49 (d, J = 8.0Hz, 2H), 7.45–7.39(m,1H),7.26(t,J=8.8Hz,2H),7.20(m,2H),5.56(s,2H),3.32 (d,J=6.3Hz,2H),3.28–3.23(m,2H),3.20(s,3H),1.71(p,J=6.7Hz,2H). 13 C NMR (75MHz, DMSO-d6) δ (ppm): 173.18, 166.51, 163.13, 153.10, 140.26, 135.29, 134.75, 131.98 (d, J = 9.2Hz), 129.66, 128, 123.48, 115.48 112.85,110.48,70.34,58.52,49.26,45.17,37.16,29.84.HRMS(ESI)calcd.for C 26 H 25 FN4O3[M+H] + 460.1911, found 461.1983.

[0299] Example 59 Synthesis of Final Product JM-29

[0300] Synthesis of N-(3-methoxypropyl)-4-((2-(benzenesulfonylamino)-1H-benzo[d]imidazol-1-yl)methyl)benzamide (JM-29)

[0301]

[0302] Weigh the intermediate 24 (0.2 g, 0.73 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (58.54 mg, 1.46 mmol) and stir at room temperature for 10 min. Then add the intermediate 26 (251.29 mg, 0.878 mmol) and stir at room temperature for 2-3 h until the raw material reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and dried with anhydrous Na2SO4. Purify by PE-EA system column chromatography. Obtain 0.15 g of white solid, yield 43%. mp180.1-181.3℃. 1 H NMR (300MHz, DMSO-d6) δ (ppm): 8.38 (t, J = 5.7Hz, 1H), 8.08–8.00 (m, 2H), 7.71–7.64 (m, 3H), 7.56–7.46 (m, 2H), 7.17–7.12 (m, 2H), 7 .10(m,1H),7.02(m,1H),6.92(m,1H),5.02(s,2H),3.36(s,1H),3.32(s,1H),3.29–3.23(m,2H),3.22(s,3H),1.71(p,J=6.6Hz,2H). 13 C NMR(75MHz,DMSO-d6)δ(ppm):HRMS(ESI)calcd.for C 26 H 26 FN3O4S[M+H] + 495.1628, found 496.1707.

[0303] Example 60 Synthesis of Final Product JM-30

[0304] Synthesis of (4-((2-((cyclohexylmethyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)(piperazin-1-yl)methanone (JM-30)

[0305]

[0306] Weigh intermediate 5 (0.2 g, 0.81 mmol) and dissolve it in anhydrous N,N-dimethylformamide (2 mL). Add NaOH (64.94 mg, 1.62 mmol) and stir at room temperature for 10 min. Add intermediate 35 (311.14 mg, 0.81 mmol) and keep stirring at room temperature for 2-3 h until the raw material reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and dried with anhydrous Na2SO4. Purify by PE-EA system column chromatography. Then add HCl / EA (15 mL), stir overnight at room temperature, spin dry the solvent, dissolve it with an appropriate amount of water, and adjust the solution with saturated sodium bicarbonate solution until a large amount of white solid precipitates. 0.23 g of white solid is obtained, with a yield of 63%. mp146.3-147.1℃ 1 H NMR(300MHz, DMSO-d6)δ(ppm):7.61–7.54(m,1H),7.53–7.45(m,1H),7.34(d,J=8.1Hz,2H),7.20(d,J=8.0Hz,2H),7.18–7.11(m,2H),5.44( s,2H),3.51(s,2H),3.31–3.12(m,4H),2.66(d,J=26.1Hz,4H),1.78(d,J=12.4Hz,2H),1.61(m,4H),1.27–0.89(m,6H).HRMS(ESI)calcd.for C 26 H 32 N4OS[M+H] + 448.2297, found 449.2010.

[0307] Example 61 Synthesis of Final Product JM-31

[0308] Synthesis of N-(4-((2-((4-fluorobenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)acrylamide (JM-31)

[0309]

[0310] Weigh intermediate 5 (0.2 g, 0.77 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (61.94 mg, 1.55 mmol) and stir at room temperature for 10 min. Then add intermediate 37 (185.90 mg, 0.77 mmol) and stir at room temperature for 2-3 h until intermediate 5 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and dried with anhydrous Na2SO4. Purify by PE-EA system column chromatography. Obtain 0.10 g of white solid with a yield of 31%. mp150.5-151.2℃ 1 H NMR(300MHz, DMSO-d6)δ(ppm):10.22(s,1H),8.90(d,J=1.6Hz,1H),8.15(m,1H),7.67(d,J=8.5Hz,2H),7.57–7.45(m,4H), 7.41(d,J=8.5Hz,2H),7.11(t,J=8.8Hz,2H),6.41(m,1H),6.29–6.16(m,1H),5.80–5.71(m,1H),5.55(s,2H),4.53(s,2H). 13 CNMR(75MHz,DMSO-d6)δ(ppm):173.23,163.95,156.62,145.89,140.00,135.95(d, 4 J C-F =3.0Hz),132.42,132.07,131.77,131.41(d, 3 J C-F =8.25Hz),129.41,129.33,127.87,120.35,115.78(d, 2 J C-F =21.0Hz),110.95,61.47,34.51.HRMS(ESI)calcd.for C 24 H 20 FN3OS[M+H] + 417.1311, found 419.1340.

[0311] Example 62 Synthesis of Final Product JM-32

[0312] Synthesis of N-(4-((2-((4-fluorobenzyl)thio)-1H-benzo[d]imidazol-1-yl)methyl)phenyl)propionamide (JM-32)

[0313]

[0314] Weigh intermediate 5 (0.2 g, 0.77 mmol) and dissolve it in anhydrous N, N-dimethylformamide (2 mL). Add NaOH (61.94 mg, 1.55 mmol) and stir at room temperature for 10 min. Then add intermediate 40 (185.90 mg, 0.77 mmol) and stir at room temperature for 2-3 h until intermediate 5 reacts completely. After stopping stirring, the reaction solution is diluted with a large amount of water, extracted with EA 3 times, the organic phases are combined, washed with a saturated solution of NaCl, and dried with anhydrous Na2SO4. Purify by PE-EA system column chromatography. Obtain 0.17 g of white solid with a yield of 52%. mp141.1-142.5℃. 1 H NMR(300MHz,DMSO-d6)δ(ppm):9.86(s,1H),7.60(m,1H),7.54–7.41(m,5H),7.21–7 .02(m,6H),5.27(s,2H),4.61(s,2H),2.27(q,J=7.5Hz,2H),1.04(t,J=7.6Hz,3H). 13 C NMR(75MHz,DMSO-d6)δ172.53,161.99(d, 1 J C-F =242.3Hz),151.43,143.51,139.40,136.62,134.27(d, 4 J C-F =3.0Hz),131.49(d, 3 J C-F =8.25Hz),131.05,128.07,122.29,119.68,118.31,115.74(d, 2 J C-F =21.8Hz),110.43,46.92,35.51,29.97,10.13.HRMS(ESI)calcd.for C 24 H 22 FN3OS[M+H] + 419.1468, found 420.1537.

[0315] Example 63 Biological Evaluation

[0316] (1) Culture of THP-1 cells

[0317] (1) Complete culture medium: RPMI-1640 culture medium 90%, fetal bovine serum 10%.

[0318] (2) Incubator environment: 37°C, air 95%, carbon dioxide 5%.

[0319] (3) Cell recovery: Take out THP-1 cell line (about 1 ml) from liquid nitrogen and place it in a 37°C water bath. After it is completely thawed (about 2 min), take out the cryovial, wipe dry, spray with 70% ethanol for disinfection, centrifuge (800 rpm, 5 min), gently aspirate the supernatant, add 1 ml of freshly prepared complete culture medium, blow evenly, transfer to a culture bottle with 4 ml of complete culture medium, blow evenly, and place in an incubator for culture.

[0320] (4) Cell passaging: Gently blow the cells evenly and count them using a counting plate. When the cell density reaches 800,000-1,000,000 / ml, pass them using the half-fluid change method and culture them in an incubator, passing them every 2-3 days.

[0321] (5) Cell cryopreservation: Take 5 ml of the cell suspension in good condition, transfer it to a centrifuge tube and centrifuge it (800 rpm, 5 min). Aspirate the supernatant, add 1 ml of cell freezing solution, blow it evenly, transfer it to a cryopreservation tube, seal it, and immediately store it in a liquid nitrogen tank.

[0322] (2) Cell experiments

[0323] Take THP-1 cells in good condition, transfer to a centrifuge tube for centrifugation (800rpm, 5min), discard the supernatant, add a newly prepared complete medium, blow evenly, count, supplement the medium to make the cell concentration about 500,000 / ml, add PMA to make its final concentration 100ng / ml, and blow evenly. Take a 96-well plate, add 100μl of cell suspension to each well, so that the number of cells in each well is about 50,000, blow the cells once every 10 wells to ensure that the cell concentration in each well is uniform (other specifications of well plates are proportionally enlarged to ensure consistent cell concentration). After adding, gently shake the 96-well plate to evenly disperse the cells, and place it in an incubator for 12h. Gently aspirate the supernatant with a pipette, add the pre-prepared drug solution along the wall, and add an equal amount of complete medium to the blank group and the model group. Incubate in the incubator for 24h. Prepare 4 μg / ml LPS stock solution with complete medium, add appropriate amount to each well (except blank group) to make the final concentration of LPS 100 ng / ml, and continue to culture in the incubator for 3 hours. Prepare 100 mg / ml ATP stock solution with PBS, add appropriate amount to each well to make the final concentration of ATP 5 mM, and continue to culture in the incubator for 1 hour.

[0324] To investigate the effects of compounds on the activation stage of NLRP3, THP-1 cells were seeded into well plates according to the above method, LPS was added to a final concentration of 100 ng / ml, and cultured in an incubator for 3 h. The supernatant was aspirated, and a pre-prepared 5 μM concentration of compound solution was added along the wall for 24 h, followed by LPS treatment for 3 h and ATP treatment for 1 h. The IL-1β level in the culture supernatant was determined by ELISA, and the inhibition rate was calculated accordingly. The data obtained are mean±sem (n=3) of three independent experiments.

[0325] The blank group and the model group were added with an equal amount of complete culture medium and cultured in an incubator for 24 h. ATP was added to a final concentration of 5 mM (or Nigericin was added to a final concentration of 10 μM), and culture was continued in an incubator for 1 h.

[0326] (3) Enzyme-linked immunosorbent assay (ELISA)

[0327] Taking IL-1β as an example, the detection of other proteins is similar:

[0328] (1) Prepare 7 different concentrations of IL-1β antibody standards using sample diluent, namely 250 pg / mL, 125 pg / mL, 62.5 pg / mL, 31.3 pg / mL, 15.6 pg / mL, 7.8 pg / mL, 3.9 pg / mL, and 0 pg / mL in zero well. Dilute the cell supernatant with sample diluent. Add 100 μl of standard or sample to each well, apply sealing film, and incubate on a shaker (37°C, 90 rpm) for 1.5 h.

[0329] (2) Take out the ELISA plate, spin dry, add 100 μL of biotin-labeled anti-Human IL-1β antibody working solution (1×) to each well, affix a sealing film, and incubate on a shaker (37°C, 90 rpm) for 1 h.

[0330] (3) Take out the ELISA plate, spin dry, and wash with buffer (1×) three times, adding no less than 300 μL to each well, each time for about 1 min. Add 100 μL of the pre-prepared ABC working solution (1×) to each well, apply a sealing film, and incubate in a shaker (37°C, 90 rpm) for 0.5 h.

[0331] (4) Take out the ELISA plate, spin dry, and wash with buffer (1×) 5 times, adding no less than 300 μL to each well, each time for about 1-2 minutes. Add 90 μL of 37°C preheated TMB colorimetric solution to each well, apply a sealing film, wrap with tin foil, and incubate on a shaker (37°C, 90 rpm) for 15-20 minutes.

[0332] (5) Take out the ELISA plate, add 100 μL of TMB stop solution to each well, and measure the OD value (450 nm) with an ELISA reader.

[0333] (6) Using the zero well as the control, establish the standard curve and calculate the concentration. Inflammatory factor inhibition rate % = [1-(sample absorbance-blank absorbance) / (model absorbance-blank absorbance)] × 100%.

[0334] (4) CCK-8 experiment

[0335] Take the differentiated macrophage THP-M. Set up blank group, model group and drug group (6 gradients: 3.125μM, 6.25μM, 12.5μM, 25μM, 50μM, 100μM). Discard the supernatant, add 100μL complete culture medium to the blank group and model group, and add the pre-prepared drug solution in equal amounts to the drug group. After 48h of culture, add 10μl CCK-8 solution to each well and continue to culture for 4h. Detect the absorbance value at 450nm with an enzyme marker. Cell proliferation inhibition rate % = [(control well absorbance - experimental well absorbance) / (control well absorbance - blank well absorbance)] × 100%.

[0336] Table 1

[0337]

[0338]

[0339] Note: a. In THP-M cells, after treatment with 5 μM compound for 24 hours, followed by LPS treatment for 3 hours and ATP treatment for 1 hour, the IL-1β level in the culture supernatant was measured by ELISA, and the inhibition rate was calculated accordingly. The data obtained are mean±sem (n=3) of three independent experiments; b. The cytotoxicity of the target compound was detected by CCK-8 method. TC 50 Indicates the concentration of compound corresponding to half of the cells are viable; c.NA: not available.

[0340] (5) Inhibitory activity of JM-31 on NLRP3 inflammasome in THP-M cells

[0341] In order to evaluate the anti-inflammatory activity of JM-31 small molecule on NLRP3 inflammasome, ELISA experiment was used to measure the half inhibitory concentration of JM-31 on NLRP3 inflammasome. Figure 1As shown, the compound was prepared into a solution according to a concentration gradient of 0.125 μM, 0.25 μM, 0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 10 μM, and 20 μM. The compound was administered to THP-M cells at a 24-h administration time. After treatment with LPS for 3 hours and ATP for 1 hour, the cell supernatant was collected and the concentration of cleaved IL-1β in the supernatant was detected by ELISA kit. Finally, the anti-inflammatory activity IC of JM-31 on NLRP3 inflammasome was calculated. 50 The results showed that the half inhibitory concentration of JM-31 against NLRP3 inflammasome was 1.28 μM, and its activity was significantly better than that of I-19 (IC 50 =17.40 μM) and II-8 (IC 50 =3.33 μM).

[0342] (6) Inhibitory effect of compound JM-31 on NLRP3 inflammasome

[0343] In order to gain a deeper understanding of the potential inhibitory effect of compound JM-31 on the activation process of NLRP3 inflammasome, this application used protein immunoblotting to evaluate the regulatory effect of JM-31 on the expression level of core proteins in the NLRP3 inflammasome signaling pathway. Different concentrations of JM-31 (0.5μM, 1μM, 10μM) were administered to THP-1 cells for 24h, and the expression levels of key proteins in the pathway were measured. The results are shown in Figure 2 As shown in the results, JM-31 showed an inhibitory effect on the production of both IL-1β and caspase-1, especially on the secretion of IL-1β. These findings suggest that JM-31 may exert its anti-inflammatory biological activity by intervening in the activation of the NLRP3 inflammasome. Further analysis showed that although JM-31 had no effect on the levels of NLRP3 and ASC proteins, it had a slight inhibitory trend on the expression levels of pro-IL-1 and βpro-caspase-1. This suggests that the inhibitory effect of JM-31 on the NLRP3 inflammasome is not limited to the inflammasome pathway itself, but may also involve the regulation of the upstream inflammatory factor formation process. Therefore, JM-31 may exert its anti-inflammatory effect through multiple mechanisms, which provides valuable information for further study of its potential anti-inflammatory therapeutic agent.

[0344] (7) Inhibitory effect of compound JM-31 on the activation phase of NLRP3 inflammasome

[0345] In order to explore the role of JM-31 in the activation stage of NLRP3 inflammasome, different concentrations of JM-31 (0.5μM, 1μM, 10μM) were administered to THP-M cells before and after LPS treatment. The administration time was 24h. The activation of the signaling pathway in the inflammatory response was simulated by activating the NLRP3 inflammasome with LPS and ATP. The IL-1β level in the supernatant was then quantitatively analyzed by ELISA. Figure 3 As shown in the figure, in both experiments, compared with the control group, the drug-treated group significantly reduced the IL-1β content in a concentration-dependent manner. The above results indicate that JM-31 has significant anti-inflammatory activity in both the initiation and activation stages of NLRP3 inflammasomes.

[0346] (8) Effect of compound JM-31 on the activation phase of NLRP3 inflammasome

[0347] The inflammatory response triggered by the NLRP3 inflammasome depends on the presence of specific proteins, and the key components involved include NLRP3 and pro-IL-1β. In the early stages of NLRP3 inflammasome activation, ensuring the synthesis of these proteins is a crucial step. In order to explore the effect of compound JM-31 on the initiation phase of the NLRP3 inflammasome, we detected the mRNA levels of NLRP3 and IL-1β by real-time fluorescence quantitative PCR (RT-qPCR). We administered different concentrations of JM-31 (1μM, 5μM, 10μM) to THP-M cells for 24h, followed by LPS stimulation for 3h, and finally using GAPDH as an internal reference to detect the mRNA levels of NLRP3 and IL-1β. The results are shown in the figure. Figure 4 As shown, compared with the control group, the mRNA level of the inflammatory factor IL-1β in the experimental group was significantly reduced after treatment with different concentrations of drugs, and this decrease was concentration-dependent, while no significant changes were observed in the mRNA level of NLRP3. These results indicate that compound JM-31 may target IL-1β in the initiation phase, inhibit its expression, and thus reduce the production of inflammatory mediators.

Claims

1. A compound represented by general formula (I) or (II) or a pharmaceutically acceptable salt thereof: in, R 1 for R a is C1-C6 alkylene or -SO2-, R b is a halogen; R 2 for R C is H, C1-C6 alkyl, halogen or -NO2; R d for P is 1-5; q is 0-3; Among them, L is R e is -S-, -SO-, -SO2- or -NH-; R f is absent, C1-C6 alkylene, -SO2- or -CO-; R 3 for R g It is a benzene ring, a 4-6 membered aliphatic ring or a 4-5 membered heterocyclic ring containing an oxygen atom; R h is halogen, H, C1-C6 alkyl, C1-C6 alkoxy, -CN, trifluoromethyl or -O-CF3; R 4 for R i It is C1-C6 alkyl or C2-C4 alkenyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: R 1 for R a is methylene or -SO2-, R b is F, Cl, Br or I; R 2 for R C is H, F, Cl, Br or I, methyl, propyl, -NO2; R d for p is 1, 2, 3, 4 or 5; q is 0, 1, 2 or 3.

3. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, characterized in that: R 1 Selected from: R 2 Selected from:

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: L is R e is -S-, -SO-, -SO2- or -NH-; R f is absent, methylene, -SO2- or --CO-; R 3 for R g It is a benzene ring, a cyclopentyl group, a cyclohexyl group or a 4-membered heterocyclic ring containing one oxygen atom and three carbon atoms; R h is F, Cl, Br, I, H, methyl, methoxy, -CN, trifluoromethyl, -O-CF3; R 4 for R d for P is 1, 2, 3, 4 or 5; q is 0, 1, 2 or 3; R i It is ethyl or vinyl.

5. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, characterized in that: L is selected from: R 3 Selected from: R 4 Selected from:

6. A compound or a pharmaceutically acceptable salt thereof, selected from any of the following structures:

7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

8. Use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating NLRP3 inflammasome-related diseases.

9. The use according to claim 8, characterized in that: The NLRP3 inflammasome-related diseases are selected from chronic inflammation, autoimmunity, metabolic diseases, neurodegenerative diseases, gout, pseudogout, atherosclerosis, non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, type 2 diabetes, Alzheimer's disease, Parkinson's disease, multiple sclerosis, kidney damage, renal fibrosis, acute and chronic heart failure, liver fibrosis, liver damage, inflammatory bowel disease, rheumatoid arthritis, cardiovascular and cerebrovascular diseases.

10. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof in the preparation of an NLRP3 inflammasome inhibitor.

Citation Information

Cited By

  • Benzimidazole compound and use thereof

    WO2026045547A1